Aura Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company developing precision therapies for solid tumors, has announced its participation in two upcoming investor conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, where senior management will engage in one-on-one investor meetings. Additionally, Aura will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring both investor meetings and a virtual presentation by CEO Elisabet de los Pinos, PhD.
The virtual presentation at the H.C. Wainwright conference will be available at 7:00 am ET on September 9, 2024, accessible via the company's website and the conference platform. This presentation will remain archived on Aura's website for 90 days following the event, providing extended access for interested parties.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AURA gained 1.55%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Members of Aura’s senior management team will participate in one-on-one investor meetings.
- H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024.
Members of Aura’s senior management team will participate in one-on-one investor meetings. A virtual presentation by Elisabet de los Pinos, PhD, Chief Executive Officer, will be available on Monday, September 9, 2024 at 7:00 am ET at https://journey.ct.events.
The presentation at the H.C. Wainwright conference will also be available at such time on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where it will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in an ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage choroidal melanoma. Bel-sar is also being evaluated in additional solid cancers, including bladder cancer. Our mission is to develop vision and organ-sparing therapies to improve patient outcomes in cancer. Aura is headquartered in Boston, MA. For more information, visit aurabiosciences.com. Visit us @AuraBiosciences and on LinkedIn.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
FAQ
What investor conferences is Aura Biosciences (AURA) attending in September 2024?
Will Aura Biosciences (AURA) be presenting at the H.C. Wainwright conference?
How can investors access Aura Biosciences' (AURA) presentation from the H.C. Wainwright conference?
How long will Aura Biosciences' (AURA) presentation from the H.C. Wainwright conference be available online?
